- The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits
- Another long-standing concern among service personnel is the treatment of concussive brain injuries
- Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm
- Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on its demonstrated ability to cross the blood-brain barrier
U.S. military service members’ healthcare concerns landed a new place in the spotlight during the past month when outraged veterans and veteran-friendly politicians called attention to a sudden reversal of fortune for a Congressional bill that promised expanded benefits to service members exposed to environmentally hazardous burn pits used in Iraq, Afghanistan, and elsewhere in the years after Sept. 11, 2001.
The bill was slated to label 23 diseases as presumed to be linked to military service, which would have made it easier for veterans to receive expedited health services and disability compensation without having to prove their illness was service-related. But after initially garnering the votes it needed to pass, a required revote unexpectedly handed it a significant defeat that proponents blamed on political posturing (https://ibn.fm/qdgPl).
Although the controversy’s passions pressured senators to reverse course again and grant the bill success as they’d originally intended, the bill’s proponents weren’t quick to forget the difficulties veterans sometimes face over access to healthcare (https://ibn.fm/7FQkj). Because of the novel nature of military service and tools, veterans’ medical concerns sometimes fall into the realm of unmet needs, whether because of political divisions or the simple lack of effective science to provide a treatment.
Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) has been advancing a proposed solution for another, more common medical concern afflicting veterans — brain injury from concussive forces.
Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in.
No U.S. Food and Drug Administration (“FDA”)-approved drug treatment exists for concussions and medical providers are generally left to rely on prescribed rest to help patients recover, but if Odyssey’s product can be established as safe and effective it will open doors to first-of-its-kind responsiveness that may benefit not only service members, but athletes and ground-level fall victims as well.
PRV-002 has already passed a series of tests in lab animal work and is currently being tested on human volunteers for safety, moving from a Single Ascending Dosing (“SAD”) stage to a Multiple Ascending Dosing (“MAD”) stage in which the volunteers will be treated once daily for five straight days. Once the safety testing is completed, Odyssey expects to launch into a Phase II testing designed to show its product is not only safe but demonstrably effective in treating concussed patients, using volunteer military service members for the trial.
“We are actively identifying and assisting with Phase II military trial site setup,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated in a July 12 news release about the testing program (https://ibn.fm/PMC10). “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.”
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.